>>Description of the research protocol "BAY 80-6946/17067"

A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) - CHROnoS-3
Phase III study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Hémato-onco
Brugmann identifier : BAY 80-6946/17067
EudraCT identifier : 2013-003893-29


Involved department : Hemato-oncology
Principal investigator : Efira/Nifosi
Sponsor : Bayer
Contact : Clinical Research Unit

>This protocol was approved by the Brugmann (CE central) ethics committee.